Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.
about
Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxisAcid suppression and the risk of Clostridium difficile infectionCurrent Trends in the Epidemiology and Outcomes of Clostridium difficile InfectionGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesProton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control studyProton pump inhibitors alter the composition of the gut microbiotaClostridium difficile infection in inflammatory bowel disease: challenges in diagnosis and treatment.Clostridium difficile Infection and Fecal Microbiota Transplant.Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.Learning Data-Driven Patient Risk Stratification Models for Clostridium difficile.Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors.Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis.Epidemiology of Clostridium difficile infectionImpact of Clostridium difficile infection on inflammatory bowel disease outcome: a review.Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea.Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis.Proton pump inhibitors: Risks of long-term use.Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility.The impact of proton pump inhibitors on the human gastrointestinal microbiomeAdvances in the evaluation and management of esophageal disease of systemic sclerosis.Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.Clostridium difficile infection in the community: are proton pump inhibitors to blame?Asymptomatic carriers of toxigenic C. difficile in long-term care facilities: a meta-analysis of prevalence and risk factorsClostridium difficile: improving the prevention paradigm in healthcare settings.Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy.Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich.Proton pump inhibitors affect the gut microbiome.A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors.Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based StudyAdverse Event Reporting for Proton Pump Inhibitor Therapy: An Overview of Systematic Reviews.Reducing co-administration of proton pump inhibitors and antibiotics using a computerized order entry alert and prospective audit and feedback.An Outbreak of Clostridium difficile Ribotype 027 Associated with Length of Stay in the Intensive Care Unit and Use of Selective Decontamination of the Digestive Tract: A Case Control Study.Halitosis and helicobacter pylori infection: A meta-analysis.Epidemiology and outcome of Clostridium difficile infections in patients hospitalized in Internal Medicine: findings from the nationwide FADOI-PRACTICE study.National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals.U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.Clostridium difficile: an emerging pathogen in children.Fecal transplant in refractory Clostridium difficile colitis.Defining Appropriate Use of Proton-Pump Inhibitors Among Medical Inpatients.
P2860
Q26768234-7B2E931F-E2EB-4A43-82AB-7C235F0FE320Q26823599-5BD62C05-B895-4B88-8D94-B81E6E209476Q26996462-EDC6DF54-E7B0-4D7C-87BC-DF5810742DACQ27026351-C2367C92-2ECF-4363-9C24-25C90CD9791CQ28543390-8D4D4872-B7E4-4E54-8AFC-DA5FB8C5DB21Q28603378-DE972724-F006-4EEE-B51D-41C3556F58E8Q30235905-37E10D2F-0496-43A2-B8CA-0B7AE7F0F95BQ30240065-5A2DB14E-4388-434E-A5AD-47F0250AA949Q30619561-1B0214AD-4CEE-4824-9A81-6F5BFAA94497Q30903148-D5927386-BFEE-4100-993D-F218D330A95CQ31157434-9A367AFA-25EB-4062-A344-EFB5E11EC949Q33666086-1D9AC3FA-A455-45C8-8CF8-8F20DC38694BQ33767958-A00E85B2-1396-4F13-806E-99D9151631F6Q34027474-E9F5C636-8139-402A-8B69-4F16AF67BE66Q34137328-815EC010-5DC6-44E9-AFE1-570C80D43DFCQ34499198-CBF4FED9-79C4-4A40-9C34-AA0D00634B44Q34510524-D8D7855D-A37E-4CD0-80DB-2CBB3877576AQ34549406-60B32D87-4EC4-45AC-8183-4DAE0BA090F8Q34566765-BBF8DACF-8621-489D-8C87-268AA34B418EQ34625008-C2659629-8B42-4832-BCCB-08EDD4B2B0FFQ34666835-07EABE26-F1D1-4660-9E7C-DC484633AB45Q34951199-B254A4C2-7AC2-4744-87C2-509F358D355BQ35031254-DEB396FD-A58B-4935-ABE1-98B4B818A415Q35112873-B589B6A9-1E37-4696-A0D2-2E2C3188EB62Q35222472-41A0CFC0-DD84-419C-9955-4B8A69740433Q35260563-D40752AB-22E5-4180-B8D2-8A75CED70DB7Q35450849-F4599AD0-1D04-431C-A9E6-68F8658855BEQ35866595-F7D596B8-FF64-4C9B-BD30-CA1E314B56B6Q35938718-E82F3076-EEEE-4882-9EA3-F17F75214B28Q35999704-523467DE-3BC4-4973-8A69-7A3F95414D8AQ36020285-DA67AB82-2BE0-4991-A0C0-0AC4AEE64EFAQ36083653-E0227041-F82B-4930-B655-63BD43F606FDQ36105911-582FBE94-664D-496B-B510-3C67A6862CE1Q36148129-FBCFFF40-5560-4B59-B042-B76051BBF53DQ36186012-F19434A2-BA09-4455-92E5-9475F4B2ABC7Q36195428-4536CE56-8921-45EE-A10E-6CB875E0E8E8Q36374829-E9BF2359-390B-4B29-9C39-F7828CF690D3Q36533541-8B5EF8BC-8822-402E-AC15-DAF7BEC0A25DQ36647979-41B491D0-4A08-4C66-820D-A8168BE00BD5Q36717591-BB478292-21D4-40BF-9FAC-D6D9089D4816
P2860
Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clostridium difficile-associat ...... itor therapy: a meta-analysis.
@en
Clostridium difficile-associat ...... itor therapy: a meta-analysis.
@nl
type
label
Clostridium difficile-associat ...... itor therapy: a meta-analysis.
@en
Clostridium difficile-associat ...... itor therapy: a meta-analysis.
@nl
prefLabel
Clostridium difficile-associat ...... itor therapy: a meta-analysis.
@en
Clostridium difficile-associat ...... itor therapy: a meta-analysis.
@nl
P2093
P2860
P921
P356
P1476
Clostridium difficile-associat ...... itor therapy: a meta-analysis.
@en
P2093
Murray N Ehrinpreis
Sailajah Janarthanan
P2860
P2888
P304
P356
10.1038/AJG.2012.179
P407
P577
2012-06-19T00:00:00Z
P5875
P6179
1009988618